12.12
-0.16(-1.30%)
Currency In USD
| Previous Close | 12.28 |
| Open | 12.49 |
| Day High | 12.52 |
| Day Low | 12.12 |
| 52-Week High | 19.58 |
| 52-Week Low | 4.88 |
| Volume | 6,401 |
| Average Volume | 201,577 |
| Market Cap | 263.89M |
| PE | -4.79 |
| EPS | -2.53 |
| Moving Average 50 Days | 13.73 |
| Moving Average 200 Days | 12.05 |
| Change | -0.16 |
If you invested $1000 in Aardvark Therapeutics, Inc. Common Stock (AARD) since IPO date, it would be worth $858.14 as of February 13, 2026 at a share price of $12.28. Whereas If you bought $1000 worth of Aardvark Therapeutics, Inc. Common Stock (AARD) shares 6 months ago, it would be worth $1,096.43 as of February 13, 2026 at a share price of $12.28.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
2 hours ago
SAN DIEGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the
Aardvark Therapeutics Announces Leadership Appointments
GlobeNewswire Inc.
Yesterday at 1:00 PM GMT
SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the
Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer
GlobeNewswire Inc.
Yesterday at 1:00 PM GMT
SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the